miRNAs associated with prostate cancer risk and progression.
Prostate cancer is the most common malignancy among men in the US. Though considerable improvement in the diagnosis of prostate cancer has been achieved in the past decade, predicting disease outcome remains a major clinical challenge. Recent expression profiling studies in prostate cancer suggest microRNAs (miRNAs) may serve as potential biomarkers for prostate cancer risk and disease progression. miRNAs comprise a large family of about 22-nucleotide-long non-protein coding RNAs, regulate gene expression post-transcriptionally and participate in the regulation of numerous cellular processes. In this review, we discuss the current status of miRNA in studies evaluating the disease progression of prostate cancer. The discussion highlights key findings from previous studies, which reported the role of miRNAs in risk and progression of prostate cancer, providing an understanding of the influence of miRNA on prostate cancer. Our review indicates that somewhat consistent results exist between these studies and reports on several prostate cancer related miRNAs. Present promising candidates are miR-1, -21, 106b, 141, -145, -205, -221, and -375, which are the most frequently studied and seem to be the most promising for diagnosis and prognosis for prostate cancer. Nevertheless, the findings from previous studies suggest miRNAs may play an important role in the risk and progression of prostate cancer as promising biomarkers.
Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.|Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA.
Hung N
HN
Luu
Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Hui-Yi
HY
Lin
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Karina Dalsgaard
KD
Sørensen
Department of Biological Sciences, Hunter College of The City University of New York, New York, NY, 10065, USA.
Olorunseun O
OO
Ogunwobi
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Nagi
N
Kumar
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Ganna
G
Chornokur
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Catherine
C
Phelan
Department of Pharmacology and Toxicology, James Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, 40202, USA.
Dominique
D
Jones
Department of Pharmacology and Toxicology, James Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, 40202, USA.
LaCreis
L
Kidd
Australian Prostate Cancer Research Centre-QLD, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
Jyotsna
J
Batra
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.|Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Kosj
K
Yamoah
Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Anders
A
Berglund
Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Robert J
RJ
Rounbehler
Research Center for Cell Fate Control, College of Pharmacy, Sookmyoung Women's University, Seoul, Republic of Korea.
Mihi
M
Yang
Department of Internal Medicine, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Sang Haak
SH
Lee
Department of Internal Medicine, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Nahyeon
N
Kang
Department of Internal Medicine, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Seung Joon
SJ
Kim
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA. Jong.Park@moffitt.org.
Jong Y
JY
Park
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.|Department of Pharmacy, Federal University of Sergipe, Rodovia Marechal Rodon, Jardim Rosa Elze, Sao Cristóvão, Brazil.
Giuliano
G
Di Pietro
D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics*
D035683:MicroRNAs